BiologicalDrug
Alpha 1-Antitrypsin clinical trials
Also written Alpha1-Proteinase Inhibitor, Prolastin-C, Zemaira and BAY 10-5233.
- studies test it
- 50
- open now
- 4
- in phase 3
- 14
- first study started
- 2003
Keep track of what changes. Save the alpha 1-Antitrypsin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Studies by the year they started
50 studies that test it; most in 2014 (6)
| Year | Studies |
|---|---|
| 2003 | 2 |
| 2004 | 1 |
| 2006 | 5 |
| 2010 | 4 |
| 2011 | 2 |
| 2012 | 4 |
| 2013 | 4 |
| 2014 | 6 |
| 2015 | 1 |
| 2016 | 6 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
- Phase 2
- 30
- Phase 3
- 14
- Phase 4
- 8
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 27 · Other 23
Grifols Therapeutics LLC (12) · Baxalta now part of Shire (5) · CSL Behring (4) · Kamada, Ltd. (3) · Institute for Human Genetics and Biochemistry (2) · Rabin Medical Center (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · University of Minnesota (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses alpha 1-Antitrypsin is read from its arms, and is right about nine times in ten.
Testing it · 50
- Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)RecruitingPhase 4CSL BehringNCT07326592Written as CE1226
- Effect of Alpha-1 Antitrypsin Supplementation on Alcohol-Associated HepatitisRecruitingPhase 2Medical University InnsbruckNCT06582329Written as Alfa1 Antitrypsin
- Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin DeficiencyEnrolling by invitationPhase 3Grifols Therapeutics LLCNCT02796937Written as Alpha-1 MP
- Zemaira Eosinophilic Esophagitis Pilot StudyRecruitingPhase 2Children's Hospital Medical Center, CincinnatiNCT05485155Written as Alpha-proteinase inhibitor
- Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)CompletedPhase 3Grifols Therapeutics LLCNCT01983241Written as Alpha-1 MP
- The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell TransplantTerminatedPhase 2/3CSL BehringNCT03805789Written as AAT
- Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation"TerminatedPhase 3Kamada, Ltd.NCT04204252Written as Alpha 1-Antitrypsin
- Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids AloneCompletedPhase 3CSL BehringNCT04167514Written as Alpha-1 antitrypsin (AAT)
- Anti-inflammatory Therapy to Improve Outcomes After TPIATCompletedPhase 4University of MinnesotaNCT02713997Written as Alpha 1-Antitrypsin
- Bronchiectasis Alpha-1 Augmentation Trial- Modulating Airway Neutrophil FunctionCompletedPhase 4University of DundeeNCT05582798Written as Alpha 1-Proteinase Inhibitor 180mg/kg
- Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal TransplantCompletedPhase 2Massachusetts General HospitalNCT02464878Written as Alpha 1-Antitrypsin
- Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic PancreatitisCompletedPhase 1/2Medical University of South CarolinaNCT02947087Written as Prolastin-C
- A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)-EmphysemaWithdrawnPhase 4TakedaNCT05466747Written as RYMPHYSIA
- Aralast NP in Islet TransplantCompletedPhase 1/2University of AlbertaNCT02520076Written as Alpha-1 Antitrypsin
- Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)CompletedPhase 1/2Grifols Therapeutics LLCNCT02870348Written as Alpha-1 MP
- Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin DeficiencyCompletedPhase 1/2Grifols Therapeutics LLCNCT02870309Written as Alpha-1 MP
- GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage StudyCompletedPhase 3Baxalta now part of ShireNCT02525861Written as GLASSIA
- Therapy to Elevate CD4 Counts in HIV-1 DiseaseCompletedPhase 2/3Institute for Human Genetics and BiochemistryNCT01370018Written as alpha-1-Proteinase Inhibitor
- A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHDCompletedPhase 2John LevineNCT03459040Written as Alpha 1-Antitrypsin
- Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19CompletedPhase 2Instituto Grifols, S.A.NCT04495101Written as Prolastin
See all 50 studies that test alpha 1-Antitrypsin →
As the comparator · 2 — what is tested is compared with alpha 1-Antitrypsin
- Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD EmphysemaCompletedPhase 2SanofiNCT05856331Written as Zemaira
- Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin DeficiencyWithdrawnPhase 2OctapharmaNCT03385395Written as Glassia
Codes
What other systems call alpha 1-Antitrypsin · ClinicalTrials.gg INT006929
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000515 | alpha 1-Antitrypsin | One source ClinicalTrials.gov |
| RxNorm | 991743 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.